8-(4-Fluoro-benzyl)-2-furan-2-yl-8H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-ylamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并嘧啶类
• 英文名称: 8-(4-Fluoro-benzyl)-2-furan-2-yl-8H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-ylamine
• 英文别名: 8-FB-PTP；5-Amino-8-(4-fluorobenzyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine；11-[(4-fluorophenyl)methyl]-4-(furan-2-yl)-3,5,6,8,10,11-hexazatricyclo[7.3.0.02,6]dodeca-1(12),2,4,7,9-pentaen-7-amine
• 化学式: C₁₇H₁₂FN₇O
• 分子量: 349.327
• InChiKey: BJALMNZBJQDVQK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  100
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-呋喃甲酰肼 在 对甲苯磺酸 作用下， 以 二苯醚 为溶剂， 反应 4.0h， 生成 8-(4-Fluoro-benzyl)-2-furan-2-yl-8H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-ylamine
  参考文献：
  名称：

  Synthesis of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidines, pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines and 1,2,4-triazolo[5,1-i]purines: new potent adenosine A2 receptor antagonists

  摘要：

  A number of 2- or 4-fluorobenzylderivatives of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidine, pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine and 1,2,4-triazolo[5,1-i] purine have been synthesized. The interaction with the adenosine A2 and A1 receptors was evaluated using selected biological assays . The highest degree of activity was displayed by the 5-amino-2-(2-furyl)-7-(or 8-)-fluorobenzyl-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine 13e, f and 18e, f and -3-fluorobenzyl-1-2-4-triazolo[5,1-i] purines 19e, f. The compound 18f was found to be the most potent A2 antagonist in our series with a selectivity similar to that of the reference compound CGS 15943, but with 75-fold more activity in the platelet aggregation model.

  DOI：

  10.1016/0223-5234(93)90087-u

文献信息

• Medicinal compositions promoting bowel movement
  申请人：——

  公开号：US20030171383A1

  公开（公告）日：2003-09-11

  The present invention provides a medicament having a gentle but strong defecation-promoting action without causing diarrhea. That is, it provides a defecation-promoting agent comprising a compound having an adenosine A 2 receptor antagonism, preferably an adenosine A 2b receptor antagonism, or a salt thereof.

  本发明提供了一种药物，具有温和而强效的促进排便作用，而不会引起腹泻。也就是说，提供了一种促进排便的药剂，包括一种具有腺苷A2受体拮抗作用的化合物，最好是腺苷A2B受体拮抗作用，或其盐。
• Pyrimidone compounds and pharmaceutical compositions containing the same
  申请人：——

  公开号：US20040259865A1

  公开（公告）日：2004-12-23

  The present invention provides a medicament having a gentle but strong defecation-promoting action without causing diarrhea. That is, it provides a defecation-promoting agent comprising a compound having an adenosine A 2 receptor antagonism, preferably an adenosine A 2b receptor antagonism, or a salt thereof.

  本发明提供了一种药物，具有温和但强效的促进排便作用，而不会引起腹泻。也就是说，它提供了一种促进排便的药剂，包括具有腺苷A2受体拮抗作用的化合物，优选为腺苷A2b受体拮抗剂或其盐。
• Pharmaceutical composition promoting defecation
  申请人：Yasuda Masahiro

  公开号：US20060270674A1

  公开（公告）日：2006-11-30

  The present invention provides a medicament having a gentle but strong defecation-promoting action without causing diarrhea. That is, it provides a defecation-promoting agent comprising a compound having an adenosine A 2 receptor antagonism, preferably an adenosine A 2b receptor antagonism, or a salt thereof.

  本发明提供了一种药物，具有温和而强效的促排便作用，而不会引起腹泻。即，提供了一种促排便剂，包括具有腺苷A2受体拮抗作用的化合物，优选为腺苷A2b受体拮抗作用的化合物或其盐。
• REMEDY FOR PARKINSON'S DISEASE
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP0666079A1

  公开（公告）日：1995-08-09

  A remedy for Parkinson's disease, which contains a polycyclic compound represented by general formula (I) or (II), or a pharmacologically acceptable salt thereof as the active ingredient. In formula (I) R¹ represents hydrogen, lower alkyl or lower alkanoyl; R² resents hydrogen, lower alkyl, lower alkenyl, cycloalkyl, aryl, aralkyl or heterocycle; R³ represents heterocycle; X represents a single bond, O, S, S(O), S(O)₂ or NR⁴, wherein R⁴ represents hydrogen, lower alkyl, etc.; and A represents N or CR⁵, wherein R⁵ represents hydrogen or lower alkyl. In formula (II) R⁶ represents aryl or heterocycle; Y represents O, S or NR⁷, wherein R⁷ represents hydrogen or lower alkyl; R⁸ represents hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aryl, aralkyl or heterocycle; and B represents together with the two neighboring groups a mono- or bicyclic carbon or hetero ring.

  一种治疗帕金森病的药物，它含有通式(I)或(II)代表的多环化合物或其药理学上可接受的盐作为活性成分。在式(I)中，R¹代表氢、低级烷基或低级烷酰基；R²代表氢、低级烷基、低级烯基、环烷基、芳基、芳烷基或杂环；R³代表杂环；X代表单键、O、S、S(O)、S(O)₂或NR⁴，其中R⁴代表氢、低级烷基等；A代表N或CR⁵，其中R⁵代表氢或低级烷基。在式 (II) 中，R⁶ 代表芳基或杂环；Y 代表 O、S 或 NR⁷，其中 R⁷ 代表氢或低级烷基；R⁸ 代表氢、低级烷基、低级烯基、低级炔基、环烷基、芳基、芳烷基或杂环；以及 B 与两个相邻基团一起代表单环或双环碳环或杂环。
• PURINE DERIVATIVES AND ADENOSINE A2 RECEPTOR ANTAGONISTS SERVING AS PREVENTIVES/REMEDIES FOR DIABETES
  申请人：Eisai Co., Ltd.

  公开号：EP1054012A1

  公开（公告）日：2000-11-22

  The present invention provides a preventive or therapeutic agent of a new type for diabetes mellitus and diabetic complications on the basis of an adenosine A2 receptor antagonistic action. A purine compound represented by the formula (I), its pharmacologically acceptable salt or hydrates thereof has an adenosine A2 receptor antagonistic action and is useful for prevention or therapy of diabetes mellitus and diabetic complications. In addition, adenosine A2 receptor antagonists having different structures from those of the compounds described above, for example KW6002, are also effective for prevention or therapy of diabetes mellitus and diabetic complications. In the formula, W is -CH2CH2-, -CH=CH- or -C≡C-; R1 is: (in the formula, X is hydrogen atom, hydroxyl group, a lower alkyl group, a lower alkoxy group, etc.; and R5 and R6 are the same as or different from each other and each represents hydrogen atom, a lower alkyl group, a cycloalkyl group, etc.) and the like; R2 is an amino group, etc. which may be substituted with a lower alkyl group, etc.; R3 is a cycloalkyl group, an optionally substituted aryl group, etc.; and R4 is a lower alkyl group, etc.

  本发明提供了一种基于腺苷 A2 受体拮抗作用的新型糖尿病和糖尿病并发症预防或治疗剂。 由式（I）代表的嘌呤化合物、其药理上可接受的盐或其水合物具有腺苷 A2 受体拮抗作用，可用于预防或治疗糖尿病和糖尿病并发症。此外，与上述化合物结构不同的腺苷 A2 受体拮抗剂，例如 KW6002，也可有效预防或治疗糖尿病和糖尿病并发症。 式中，W为-CH2CH2-、-CH=CH-或-C≡C-；R1为： (式中，X 是氢原子、羟基、低级烷基、低级烷氧基等；R5 和 R6 彼此相同或不同，各自代表氢原子、低级烷基、环烷基等）等；R2 是可被低级烷基等取代的氨基等；R3 是环烷基、任选取代的芳基等；R4 是低级烷基等。